Mylan Agrees To Separate Settlements With N.C., Md. Over EpiPen Sales Tactics
Attorneys general from North Carolina and Maryland announced separate settlement agreements reached with Mylan Inc. to resolve claims that the seller of the EpiPen epinephrine autoinjector (EAI) used anticompetitive tactics to...To view the full article, register now.
Already a subscriber? Click here to view full article